FENNEC PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
FENNEC PHARMACEUTICALS INC. (FENC) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$14.33 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-27
- FENNEC PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$14.33M.
- FENNEC PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$12.13M.
- FENNEC PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$10.55M.
- FENNEC PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$9.12M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$14.33M 10-K · filed 2026-03-27 |
| 2024-12-31 | -$12.13M 10-K · filed 2026-03-27 |
| 2022-12-31 | -$10.55M 10-K · filed 2023-03-29 |
| 2021-12-31 | -$9.12M 10-K · filed 2023-03-29 |
| 2020-12-31 | -$8.78M 10-K · filed 2022-02-28 |
| 2019-12-31 | -$9.00M 10-K · filed 2021-03-30 |
| 2018-12-31 | -$7.70M 10-K · filed 2020-02-14 |
| 2017-12-31 | -$5.28M 10-K · filed 2019-03-15 |
| 2016-12-31 | -$1.77M 10-K · filed 2018-03-28 |
| 2015-12-31 | $294.00K 10-K · filed 2017-03-29 |
| 2014-12-31 | -$1.33M 10-K · filed 2016-03-28 |
| 2013-12-31 | $2.62M 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |